Metastatic melanoma: chemotherapy to biochemotherapy.
Open Access
- 1 January 2002
- journal article
- review article
- Published by SAGE Publications in Cancer Control
- Vol. 9 (1) , 31-38
- https://doi.org/10.1177/107327480200900105
Abstract
Single-agent or combination chemotherapy regimens have not impacted the short median survival of patients with metastatic melanoma, and complete or durable responses are rare. Biologic response modifiers (interferon and interleukin-2) have produced durable remissions in a small cohort of patients, and phase II trials of biochemotherapy suggest more benefit.Keywords
This publication has 30 references indexed in Scilit:
- Cancer Statistics, 2001CA: A Cancer Journal for Clinicians, 2001
- Treatment of metastatic melanoma with combined chemotherapy containing cisplatin, vinblastine and dacarbazine (CVD) and biotherapy using interleukin-2 and interferon-αAnnals of Oncology, 1996
- Tamoxifen retards glycosphingolipid metabolism in human cancer cellsFEBS Letters, 1996
- Reversal of P-glycoprotein-mediated multidrug resistance by pure anti-oestrogens and novel tamoxifen derivativesBiochemical Pharmacology, 1994
- Interferon-α and interleukin-2 in the treatment of metastatic melanoma. Comparison of two phase II trialsCancer, 1993
- Cutaneous melanoma: Prognosis and treatment results worldwideSeminars in Surgical Oncology, 1992
- Tamoxifen as a single agent for advanced melanoma in postmenopausal women. A phase II study of the EORTC Malignant Melanoma Cooperative GroupMelanoma Research, 1992
- Treatment of Metastatic Malignant Melanoma with Dacarbazine plus TamoxifenNew England Journal of Medicine, 1992
- Effective combination chemo/hormonal therapy for malignant melanoma: Experience with three consecutive trialsInternational Journal of Cancer, 1992
- The importance of tamoxifen to a cisplatin-containing regimen in the treatment of metastatic melanomaCancer, 1989